ANTICOV logo The ANTICOV clinical trial responds to the urgent need to identify treatments that can be used to treat mild and moderate cases of COVID-19 early and prevent spikes in hospitalizations that could overwhelm fragile and already overburdened health systems in low- and middle-income countries.

Launched in November 2020 by the ANTICOV consortium, the study is an open-label, randomised, comparative, ‘adaptive platform trial’ that is testing the safety and efficacy of treatments in mild-to-moderate COVID-19 patients. ANTICOV aims to identify early treatments that can prevent progression of COVID-19 to severe disease and potentially limit transmission.

An adaptive platform trial is a flexible and innovative trial design that allows for treatments to be added or removed as evidence emerges.

ANTICOV researchers are actively looking to select the most promising treatments from ongoing global scientific efforts with proof of efficacy, in collaboration with the Access to COVID-19 Tools Accelerator (ACT-A) Therapeutics Partnership, co-convened by Unitaid and Wellcome on behalf of the COVID-19 Therapeutics Accelerator.

Major funding for the ANTICOV consortium is provided by the German Federal Ministry of Education and Research (BMBF) through KfW and by the global health agency Unitaid as part of ACT-A. Early support to launch the initiative was provided by the European & Developing Countries Clinical Trials Partnership (EDCTP), under its second programme supported by the European Union with additional funding from the Swedish government, and the Starr International Foundation, Switzerland.

Project updates

February 2022

ANTICOV has started the recruitment of participants to test a new promising drug combination, fluoxetine and budesonide. Read the press release

Data Safety Monitoring Board decision to stop testing the drug combination nitazoxanide and inhaled ciclesonide. Read the press release

January 2022

Patient recruitment is ongoing at 15 sites in 10 countries to test three treatment combinations: nitazoxanide with the inhaled glucocorticoid ciclesonide; ivermectin with artesunate and amodiaquine (ASAQ); and fluoxetine with the inhaled corticosteroid budesonide. More than 1200 patients have been recruited to date. Two interim analyses have been conducted, and no change to the study design was recommended. 

ANTICOV India, a study similar to ANTICOV, will be conducted at 15 sites in India, with the first patient recruited expected in early 2022. 

April 2021

ANTICOV has started the recruitment of participants to test a new potential treatment that combines the well-known antiparasitic nitazoxanide and the inhaled corticosteroid ciclesonide. The first participants in the new study arm have been recruited in the Democratic Republic of Congo (DRC) and the Republic of Guinea. In the coming weeks, additional trial sites will enrol participants in Burkina Faso, Cameroon, Côte d’Ivoire, Equatorial Guinea, Ethiopia, Ghana, Kenya, Mali, Mozambique, Sudan, and Uganda. Read the press release

November 2020

Thirteen African countries and an international network of research institutions have joined forces to launch ANTICOV, the largest COVID-19 clinical trial in mild-to-moderate outpatients in Africa. Read the press release